Furthermore, unlike its therapeutic efficacy demonstrated in other types of solid tumors such as advanced non-small cell lung cancer (45) and metastatic urothelial cancer (46), the response rate of atezolizumab (a humanized anti-PD-L1 mAb) in MSS CRCs is not encouraging (47). This evidence concerns the gene CD274 and non-small cell lung carcinoma.